aveni S.A., developer and manufacturer of market-disrupting wet deposition technologies and chemistries for 2D interconnects and 3D through silicon via packaging, today announced it has obtained results that strongly support the continued use of copper in the back end of line (BEOL) for advanced interconnects, at and beyond the 5nm technology node.
STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of both Professor Mark Dawson and Dr Paul Leeson to the Scientific Advisory Board.
AMSTERDAM, NETHERLANDS – December 6, 2017 – Synaffix BV, a biotechnology company that has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the launch of a new platform of highly potent cytotoxic ADC payloads that will be integrated into its existing ADC platform. With this expansion, Synaffix becomes a one-stop provider for technologies required to rapidly translate antibodies into proprietary ADC products.
Synaffix BV, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the granting of a key patent that encompasses the entire GlycoConnect™ process.
Biolinq today announced the close of a $10M Series A financing led by M Ventures, in collaboration with Hikma Ventures. Biolinq is a digital health company with a unique, wirelessly-enabled biosensor patch that is capable of continuously monitoring multiple biomarkers.
New Drug Target Discovered For Acute Myeloid Leukaemia
STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the publication of data in the internationally renowned scientific journal Nature linking an essential RNA-modifying enzyme to acute myeloid leukaemia (AML)
STORM Therapeutics, the drug discovery company focused on the
discovery of small molecule therapies modulating RNA epigenetics, today announced the
appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution
of its management and advisory networks as it fulfils its ambition to become the leading therapeutics
company in RNA epigenetic modulation.
PARIS, France – October 24, 2017 aveni S.A., developer and manufacturer of market disrupting wet deposition technologies and chemistries for 2D interconnects and 3D TSV packaging, today announced it has completed a €8.9M ($10.5M) capital raise from M Ventures, the corporate venture arm of Merck, along with existing investors.
Peratech, a world leader in 3D force-sensing technologies, announced it has subscribed $12.4 million (£9.2 million) to the round of funding, led by M Ventures the venture capital wing of Merck, along with Arie Capital and existing investors.
Synaffix BV announced today that ADC
Therapeutics has triggered a second target-specific license under their Commercial License
Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffix’s
proprietary site-specific antibody-drug conjugation technology. As part of the original
agreement, ADC Therapeutics retains an option to take a limited number of additional singletarget
licenses for their potential future programs.
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels as demonstrated in preclinical models. This selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency.
World ADC is pleased to announce the finalists in the 4th Annual World ADC Awards. The World ADC Awards showcase the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry. Across 9 categories the Awards will recognise the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.
Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.
VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company's lead product candidate, VXM01, has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma, a difficult-to-treat form of brain cancer. Orphan designation is designed to encourage the development of drugs to treat rare diseases and conditions and provides companies with certain incentives, including periods of market exclusivity upon approval, as well as user fee reductions or exemptions. The designation by the European Commission is for the treatment of glioma and by the US FDA for the treatment of malignant glioma.
Paris, September 12th, 2017. Synthetic DNA manufacturer DNA Script has today announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures, with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners.
- Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART
- Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential
Darmstadt, Germany, June 20, 2017 – Merck, a leading science and technology company, today announced its corporate venture arm M Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of Cancer Research UK, London, UK. M Ventures will manage the investment and will be represented on iOnctura’s board of directors.
Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr Simon Boulton, VP Scientific Strategy at Artios, will serve as Chairman.
ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the completion of a Phase 1 clinical trial aimed at evaluating the PK/PD relationship of OBE2109 combined with different doses of add-back therapy.
F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies (mAb2 TM).
M Ventures has led a $10.8 million (€9.6 million) investment in Inthera Bioscience. The series A sets the Swiss biotech up to wrap up preclinical development of a lead candidate against cancers associated with human papillomavirus (HPV).
exclusively focused on the development of industry-leading antibody-drug conjugate
(ADC) technology platforms, today announced that a key patent covering its HydraSpace™
spacer technology has been granted by the United States Patent and Trademark Office
(US 9,636,421 B2).
Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017.
Basel (Switzerland) and Mannheim (Germany), May 9, 2017 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company which in the US and Canada operates as EMD Serono, and Pfizer Inc. (NYSE: PFE) to evaluate avelumab*, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. VXM01 is an investigational oral T-cell immunotherapy designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials – one in glioblastoma and one in metastatic colorectal cancer.
Basel (Switzerland) and Mannheim (Germany), March 30, 2017 - VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data for three of its programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 being held in Washington, DC, USA, April 1-5.
Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.
I’ll admit it: Apps that remind you to take your pills are not as sexy as, say, folding laptops or MP3 toothbrushes. But they’re important. Every year an estimated 125,000 Americans die from taking their pills incorrectly, according to a 2012 study from the Annals of Internal Medicine.
LONDON and BOSTON, March 1, 2017 — Medisafe®, the leading personalized medication management platform with over three and a half million patient and caregiver registered users, announced today that it has raised a $14.5M Series B funding round led by Octopus Ventures, and joined by M Ventures, to support the company’s rapid growth and global expansion. Other investors participating from previous rounds include Pitango Venture Capital, 7wire ventures, lool Ventures, TriVentures and Qualcomm Ventures.
CAMBRIDGE, UK (24 FEB 2017) - Storm Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.
AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.
**Forbion & Seroba co-led funding, forming international consortium of M Ventures, Ysios and Sunstone
Funding to finance two Phase II trials in Parkinson’s disease**
**Geneva, Switzerland and Amsterdam, The Netherlands, February 7, 2017** - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the closing of a Series B financing round of €29 million ($31M).
Geneva, Switzerland - January 25, 2017 - ObsEva SA (ObsEva) announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "OBSV" on January 26, 2017.
Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the proposed offering.
YAVNE, Israel, January 5, 2016 - Israeli cancer apoptosis company ARTSaVIT LTD announced today that it has completed a $6.3 million Series A round of financing led by Arkin Bio Ventures and Pontifax, with participation of M Ventures, Carmel Innovation and Carmel - Haifa University Economic Corporation Ltd.